Source: European Biotechnology

Tacalyx received $7.5M in Seed Funding

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Peter Sondermann

CEO Approval Rating

70/100

Tacalyx is a Germany-based biotechnology company that researches and develops novel anti-TACA immunotherapies for the treatment of cancer.